CLOVIS ONCOLOGY, INC. [ • ] Shares of Common Stock (par value $0.001 per share) Underwriting AgreementClovis Oncology, Inc. • October 31st, 2011 • Pharmaceutical preparations • New York
Amended and Restated Strategic License Agreement by and between Avila Therapeutics, Inc. and Clovis Oncology, Inc. June 16, 2011License Agreement • October 31st, 2011 • Clovis Oncology, Inc. • Pharmaceutical preparations • New York
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. COMPANION DIAGNOSTICS AGREEMENT BETWEEN CLOVIS ONCOLOGY, INC. AND ROCHE MOLECULAR SYSTEMS, INC.Companion Diagnostics Agreement • October 31st, 2011 • Clovis Oncology, Inc. • Pharmaceutical preparations • Delaware
This COMPANION DIAGNOSTICS AGREEMENT (this “Agreement”) is made and entered into as of the latest date of signature below (the “Effective Date”) by and between Clovis Oncology, Inc., a Delaware corporation, having a place of business at 2525 28th Street, Suite 100, Boulder, CO 80301 (“Clovis Oncology”) and Roche Molecular Systems, Inc., a Delaware corporation having a place of business at 4300 Hacienda Drive, Pleasanton, California 94588 (“RMS”).
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. LICENSE AGREEMENTLicense Agreement • October 31st, 2011 • Clovis Oncology, Inc. • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT (“Agreement”) is made effective as of the 2nd day of June, 2011 (the “Effective Date”), by and between Clovis Oncology, Inc., a corporation organized and existing under the laws of Delaware with offices at 2525 28th Street, Boulder, CO 80301 (“LICENSEE”) and PFIZER Inc., a corporation organized and existing under the laws of Delaware with offices at 235 East 42nd Street, New York, NY 10017 (“PFIZER”). LICENSEE and PFIZER may, from time-to-time, be individually referred to as a “Party” and collectively referred to as the “Parties”.
OPTION GRANT NOTICE AND AGREEMENTOption Grant Notice and Agreement • October 31st, 2011 • Clovis Oncology, Inc. • Pharmaceutical preparations
Clovis Oncology, Inc. (the “Company”), pursuant to its 2011 Stock Incentive Plan (the “Plan”), hereby grants to the Holder the number of Options set forth below, each Option representing the right to purchase one share of Stock at the applicable Exercise Price (set forth below). The Options are subject to all of the terms and conditions set forth in this Option Grant Notice and Agreement (this “Agreement”) as well as all of the terms and conditions of the Plan, all of which are incorporated herein in their entirety. Capitalized terms not otherwise defined herein shall have the same meaning as set forth in the Plan.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. MASTER SERVICE AGREEMENTIndividual Project Agreement • October 31st, 2011 • Clovis Oncology, Inc. • Pharmaceutical preparations • Arizona
This Master Service Agreement (this “Agreement”) is effective March 23, 2010, (the “Effective Date”), between Ventana Medical Systems, Inc., 1910 E. Innovation Park Drive, Tucson, AZ 85755 United States (“Ventana”), and Clovis Oncology, Inc., 2525 28th Street, Suite 180, Boulder, CO 80301 (“Clovis”).
